# Regeneron Pharmaceuticals, Inc.: overview

REGN · Nasdaq · CIK 872589 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/regn.md) · [Financials](/companies/regn/financials.md) · [Filings](/companies/regn/filings.md) · [Insiders](/companies/regn/insiders.md)

Latest reported revenue: [$4.29bn](/filings/0000872589-26-000025.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000872589-26-000025).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,721](/filings/0000872589-25-000028.md) | [3,789 d](/filings/0000872589-26-000008.md) | [3,029](/filings/0000872589-26-000016.md) | [3,676](/filings/0000872589-26-000025.md) | [3,754](/filings/0000872589-25-000028.md) | [3,884 d](/filings/0000872589-26-000008.md) | [3,605](/filings/0000872589-26-000016.md) | [4,291](/filings/0000872589-26-000025.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [31.7%](/filings/0000872589-25-000028.md) | [26.1% d](/filings/0000872589-26-000008.md) | [19.5%](/filings/0000872589-26-000016.md) | [29.4%](/filings/0000872589-26-000025.md) | [27.3%](/filings/0000872589-25-000028.md) | [22.7% d](/filings/0000872589-26-000008.md) | [17.8%](/filings/0000872589-26-000016.md) | [30.1%](/filings/0000872589-26-000025.md) |
| Net margin | % | [36.0%](/filings/0000872589-25-000028.md) | [24.2% d](/filings/0000872589-26-000008.md) | [26.7%](/filings/0000872589-26-000025.md) | [37.9%](/filings/0000872589-26-000025.md) | [38.9%](/filings/0000872589-25-000028.md) | [21.7% d](/filings/0000872589-26-000008.md) | [20.2%](/filings/0000872589-26-000025.md) | [30.2%](/filings/0000872589-26-000025.md) |
| Diluted EPS | $ per share | [11.54](/filings/0000872589-25-000028.md) | not reported | [7.27](/filings/0000872589-26-000016.md) | [12.81](/filings/0000872589-26-000025.md) | [13.62](/filings/0000872589-25-000028.md) | not reported | [6.75](/filings/0000872589-26-000016.md) | [12.23](/filings/0000872589-26-000025.md) |
| Free cash flow | $m | [1,049 d](/filings/0000872589-25-000028.md) | [1,063 d](/filings/0000872589-26-000008.md) | [816](/filings/0000872589-26-000016.md) | [925 d](/filings/0000872589-26-000025.md) | [1,417 d](/filings/0000872589-25-000028.md) | [922 d](/filings/0000872589-26-000008.md) | [848](/filings/0000872589-26-000016.md) | [573 d](/filings/0000872589-26-000025.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [16.1](/filings/0001804220-24-000009.md) | [12.2](/filings/0001804220-25-000011.md) | [13.1](/filings/0000872589-26-000008.md) | [14.2](/filings/0000872589-26-000008.md) | [14.3](/filings/0000872589-26-000008.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [55.7%](/filings/0001804220-24-000009.md) | [38.9%](/filings/0001804220-25-000011.md) | [30.9%](/filings/0000872589-26-000008.md) | [28.1%](/filings/0000872589-26-000008.md) | [24.9%](/filings/0000872589-26-000008.md) |
| Net margin | % | [50.2%](/filings/0001804220-24-000009.md) | [35.6%](/filings/0001804220-25-000011.md) | [30.1%](/filings/0000872589-26-000008.md) | [31.1%](/filings/0000872589-26-000008.md) | [31.4%](/filings/0000872589-26-000008.md) |
| Diluted EPS | $ per share | [71.97](/filings/0001804220-24-000009.md) | [38.22](/filings/0001804220-25-000011.md) | [34.77](/filings/0000872589-26-000008.md) | [38.34](/filings/0000872589-26-000008.md) | [41.48](/filings/0000872589-26-000008.md) |
| Free cash flow | $bn | [6.5](/filings/0001804220-24-000009.md) | [4.4](/filings/0001804220-25-000011.md) | [3.9](/filings/0000872589-26-000008.md) | [3.7](/filings/0000872589-26-000008.md) | [4.1](/filings/0000872589-26-000008.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/regn/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2020-06-09 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 120,234 | $597.48 | $71.8m | [Form 4](/filings/0001140361-20-013625.md) |
| 2020-05-29 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 2,399,552 | $509.85 | $1.22bn | [Form 4](/filings/0001140361-20-012718.md) |
| 2020-05-29 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 20,421,899 | $509.85 | $10.41bn | [Form 4](/filings/0001140361-20-012718.md) |
| 2020-03-09 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 128,914 | $489.6532 | $63.1m | [Form 4](/filings/0001140361-20-005506.md) |
| 2019-09-10 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 172,904 | $281.1491 | $48.6m | [Form 4](/filings/0001140361-19-016600.md) |
| 2019-03-08 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 131,115 | $412.1673 | $54.0m | [Form 4](/filings/0001140361-19-004808.md) |
| 2018-09-06 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 104,552 | $406.6804 | $42.5m | [Form 4](/filings/0001140361-18-038175.md) |
| 2018-06-08 | [Sanofi](/insiders/1121404.md) | 10% owner | Sale (S) | 121,601 | $309.3057 | $37.6m | [Form 4](/filings/0001140361-18-028055.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 2,557 | $487.0108 | $1.2m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 2,681 | $485.9939 | $1.3m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 5,723 | $485.2798 | $2.8m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 2,000 | $484.21 | $968.4k | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 4,485 | $482.8734 | $2.2m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 1,302 | $481.6284 | $627.1k | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 21,360 | $480.7489 | $10.3m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 28,586 | $479.9313 | $13.7m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-25 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 3,684 | $479.1912 | $1.8m | [Form 4](/filings/0001140361-17-033562.md) |
| 2017-08-24 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 6,960 | $488.574 | $3.4m | [Form 4](/filings/0001140361-17-033310.md) |
| 2017-08-24 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 8,860 | $487.5532 | $4.3m | [Form 4](/filings/0001140361-17-033310.md) |
| 2017-08-24 | [Sanofi](/insiders/1121404.md) | 10% owner | Purchase (P) | 6,920 | $486.6264 | $3.4m | [Form 4](/filings/0001140361-17-033310.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.68bn | 9,113,506 |  | Added +165,771 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.13bn | 6,629,759 |  | Reduced −25,154 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $3.04bn | 4,871,137 |  | Added +412,899 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.01bn | 4,834,688 |  | Added +170,210 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $2.46bn | 3,940,665 |  | Added +2,216,187 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $2.38bn | 3,774,199 |  | Reduced −537,607 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.98bn | 3,175,313 |  | Added +1,454,539 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $1.73bn | 2,771,839 |  | Added +49,768 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.63bn | 2,625,810 |  | Added +18,078 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $1.26bn | 2,019,974 |  | Reduced −45,090 |

## Recent filings

[All 1,915 filings](/companies/regn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 06:50 ET | [8-K](/filings/0000872589-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000872589-26-000032 |
| 2026-10-06 | 07:51 ET | [8-K](/filings/0001104659-26-113895.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events | 0001104659-26-113895 |
| 2026-09-30 | 16:14 ET | [8-K](/filings/0001104659-26-112340.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-112340 |
| 2026-07-30 | 06:52 ET | [10-Q](/filings/0000872589-26-000025.md) | Quarterly report, period 2026-06-30 | 0000872589-26-000025 |
| 2026-07-30 | 06:48 ET | [8-K](/filings/0000872589-26-000023.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000872589-26-000023 |
| 2026-07-06 | 07:00 ET | [8-K](/filings/0001104659-26-080562.md) | 2.02 Results of operations | 0001104659-26-080562 |
| 2026-06-17 | 16:05 ET | [8-K](/filings/0001104659-26-075127.md) | 5.07 Shareholder vote results | 0001104659-26-075127 |
| 2026-04-29 | 06:54 ET | [10-Q](/filings/0000872589-26-000016.md) | Quarterly report, period 2026-03-31 | 0000872589-26-000016 |
| 2026-04-29 | 06:50 ET | [8-K](/filings/0000872589-26-000014.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000872589-26-000014 |
| 2026-04-24 | 16:02 ET | [DEF 14A](/filings/0001308179-26-000340.md) | Proxy statement, period 2026-06-12 | 0001308179-26-000340 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000872589-26-000008.md), filed Feb 4, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 872589
- Tickers: REGN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NY
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 06:56 ET. No prices; not investment advice.